Steris (STE): financials, SEC filings and peers

Steris (STE) is a health care equipment company in the Health Care sector of the S&P 500, headquartered in Dublin, Ireland.

It was founded in 1985 and joined the S&P 500 on December 23, 2019.

Its fiscal year ends in March, and its shares trade on the NYSE.

In its SEC filings it is classified as “Orthopedic, Prosthetic & Surgical Appliances & Supplies”.

Steris at a glance

Revenue (12 months): $6.2B
Revenue growth: +8.1%
Operating margin: 19.0%
Net income (12 months): $827M
Free cash flow (12 months): $937M
Cash: $531M
Debt: $1.9B
Diluted EPS (12 months): —

Twelve months to September 30, 2026, from the 10-Q filed November 5, 2026.

Latest twelve months

Over the twelve months to September 30, 2026, Steris reported revenue of $6.2 billion, up 8.1% from a year earlier.

Its operating margin was 19.0%, up 1.9 percentage points from a year earlier: for every $100 of sales, about $19 was left as operating profit.

Net income was $827 million (13.4% of revenue), 20.1% higher than a year earlier.

Operating cash flow was $1.3 billion and capital spending $353 million, leaving free cash flow of $937 million (15.2% of revenue).

At the end of the period it held $531 million in cash and $1.9 billion in debt, a net debt position of $1.4 billion.

The diluted share count fell 1.2% in a year, typically the result of buybacks.

Five-year trend

Revenue went from $3.1 billion in fiscal 2021 to $5.9 billion in fiscal 2026, about 13.8% a year.
Revenue has grown for 5 fiscal years in a row.
Operating margin has been steady, around 18.6%.
Free cash flow was positive in each of the last 6 fiscal years.

Fiscal year	2022	2023	2024	2025	2026
Revenue	$4.2B	$4.5B	$5.1B	$5.5B	$5.9B
Revenue growth	35.9%	7.4%	13.3%	6.2%	8.7%
Operating margin	11.3%	17.4%	16.3%	15.9%	18.6%
Net income	$244M	$107M	$378M	$615M	$782M
Free cash flow	$397M	$395M	$613M	$778M	$972M
Diluted EPS	$2.48	$1.07	$3.81	$6.20	$7.93

Fiscal years as reported in Steris’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

10-Q filed November 5, 2026 — quarterly report
8-K filed November 4, 2026 — Material agreement; Agreement terminated
8-K filed November 4, 2026 — Earnings results; Restructuring costs
8-K filed October 13, 2026 — Material agreement
10-Q filed August 7, 2026 — quarterly report
8-K filed August 6, 2026 — Shareholder vote results
8-K/A filed August 6, 2026 — Executive or director change
8-K filed August 5, 2026 — Earnings results; Restructuring costs

All Steris filings on SEC EDGAR

Companies like Steris

Other S&P 500 companies in Health Care Equipment:

More from Health Care

All 60 Health Care companies →

Questions about Steris

Is Steris's revenue growing?

Yes. Revenue for the twelve months to September 30, 2026 was $6.2 billion, up 8.1% from a year earlier, according to its SEC filings.

Is Steris profitable?

Yes. It earned $827 million in net income over the twelve months to September 30, 2026, a net margin of 13.4%.

Does Steris have more cash or more debt?

At September 30, 2026 it had $531 million in cash and $1.9 billion in debt, so more debt than cash.

When did Steris last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on November 5, 2026.

Which companies are similar to Steris?

In the S&P 500, Steris is grouped in Health Care Equipment within the Health Care sector. Abbott Laboratories (ABT), Baxter International (BAX), Becton Dickinson (BDX), Boston Scientific (BSX), Dexcom (DXCM) are in the same group.

Understand the numbers

Source: Steris’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.